Does Creatine Affect Lipid Profile? A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

Why It Matters

With the global sports‑nutrition market exceeding $190 billion, understanding creatine’s metabolic impact is crucial for consumers and clinicians concerned about cardiometabolic risk.

Key Takeaways

• Eight RCTs showed no significant changes in cholesterol or triglycerides.
• Pooled mean differences were small and confidence intervals crossed zero.
• Evidence certainty ranged low to very low because of bias, heterogeneity.
• Transient lipid changes in some trials were not sustained over time.
• Future large, double‑blind RCTs are required to clarify creatine’s lipid impact.

Pulse Analysis

The dietary supplement arena continues to expand rapidly, driven by athletes and health‑conscious consumers seeking performance and wellness benefits. Creatine, a staple in strength‑training regimens, has long been praised for its ergogenic properties, yet questions linger about its broader metabolic effects, especially on lipid metabolism—a key factor in cardiovascular disease risk. By aggregating data from eight randomized trials, this meta‑analysis provides a comprehensive look at how creatine interacts with cholesterol and triglyceride pathways, offering a rare evidence‑based perspective amid a market saturated with anecdotal claims.

Across the pooled studies, creatine supplementation produced negligible shifts in total cholesterol, LDL‑C, HDL‑C, and triglycerides, with mean differences ranging from a modest 2.9 mg/dL increase in total cholesterol to a 7.9 mg/dL rise in triglycerides—both statistically non‑significant. Heterogeneity was moderate for total cholesterol (I² = 46 %) and substantial for triglycerides (I² = 55 %), reflecting variations in dosing protocols, participant health status, and concurrent exercise programs. While a few trials reported transient lipid elevations or modest triglyceride reductions, these effects were inconsistent and faded over longer follow‑up periods. Mechanistically, pre‑clinical work suggests creatine could influence adipose thermogenesis and mitochondrial function, but human data have yet to translate these hypotheses into measurable lipid benefits.

For clinicians and industry stakeholders, the takeaway is clear: current evidence does not support prescribing creatine as a lipid‑lowering adjunct. The low to very low certainty ratings, driven by risk‑of‑bias concerns and imprecise estimates, underscore the need for well‑powered, double‑blind trials targeting populations with dyslipidemia or metabolic syndrome. Standardized dosing regimens, longer intervention durations, and inclusion of mechanistic biomarkers would enhance future research. Until such data emerge, creatine remains a safe, performance‑focused supplement without proven cardiometabolic advantages.